Publications by Stein Bergan
119 publications found
Original articles
Therapeutic Drug Monitoring of Intravenous Busulfan and Analytical Challenges due to the Drug Formulation Excipient PEG 400: Letter to the Editor
Ther Drug Monit (in press)
DOI 10.1097/FTD.0000000000001209, PubMed 38648662
The atorvastatin metabolite pattern in muscle tissue and blood plasma is associated with statin muscle side effects in patients with coronary heart disease; An exploratory case-control study
Atheroscler Plus, 55, 31-38
DOI 10.1016/j.athplu.2024.01.001, PubMed 38293288
Validation of a novel direct method to determine reduced adherence to atorvastatin therapy
Eur Heart J Cardiovasc Pharmacother (in press)
DOI 10.1093/ehjcvp/pvae001, PubMed 38196131
Clinical performance of volumetric finger-prick sampling for the monitoring of tacrolimus, creatinine and haemoglobin in kidney transplant recipients
Br J Clin Pharmacol, 89 (12), 3690-3701
DOI 10.1111/bcp.15870, PubMed 37537150
Plasma concentration of atorvastatin metabolites correlates with low-density lipoprotein cholesterol reduction in patients with coronary heart disease
Pharmacol Res Perspect, 11 (3), e01089
DOI 10.1002/prp2.1089, PubMed 37186070
Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19
Ther Drug Monit, 45 (2), 191-199
DOI 10.1097/FTD.0000000000001014, PubMed 35944126
Atorvastatin Metabolite Pattern in Skeletal Muscle and Blood from Patients with Coronary Heart Disease and Statin-Associated Muscle Symptoms
Clin Pharmacol Ther, 113 (4), 887-895
DOI 10.1002/cpt.2844, PubMed 36622792
Monitoring Simvastatin Adherence in Patients With Coronary Heart Disease: A Proof-of-Concept Study Based on Pharmacokinetic Measurements in Blood Plasma
Ther Drug Monit, 44 (4), 558-567
DOI 10.1097/FTD.0000000000000992, PubMed 35482468
[Estimated glomerular filtration rate as a measurement of kidney function]
Tidsskr Nor Laegeforen, 141 (1)
DOI 10.4045/tidsskr.21.0501, PubMed 35026092
Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side effects: a randomized, double-blinded crossover trial
Eur Heart J Cardiovasc Pharmacother, 7 (6), 507-516
DOI 10.1093/ehjcvp/pvaa076, PubMed 32609361
In vitro assessments predict that CYP3A4 contributes to a greater extent than CYP3A5 to prednisolone clearance
Basic Clin Pharmacol Toxicol, 129 (6), 427-436
DOI 10.1111/bcpt.13645, PubMed 34396687
Fast and reliable quantification of busulfan in blood plasma using two-channel liquid chromatography tandem mass spectrometry: Validation of assay performance in the presence of drug formulation excipients
J Pharm Biomed Anal, 203, 114216
DOI 10.1016/j.jpba.2021.114216, PubMed 34182411
Tacrolimus Measured in Capillary Volumetric Microsamples in Pediatric Patients-A Cross-Validation Study
Ther Drug Monit, 43 (3), 371-375
DOI 10.1097/FTD.0000000000000873, PubMed 33596033
Prednisolone and Prednisone Pharmacokinetics in Adult Renal Transplant Recipients
Ther Drug Monit, 43 (2), 247-255
DOI 10.1097/FTD.0000000000000835, PubMed 33181621
Measuring Intracellular Concentrations of Calcineurin Inhibitors: Expert Consensus from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Expert Panel
Ther Drug Monit, 42 (5), 665-670
DOI 10.1097/FTD.0000000000000780, PubMed 32520841
Severe Mycophenolate Intoxication in a Solid Organ Transplant Recipient-No Intervention Actually Needed
Transplant Direct, 6 (10), e609
DOI 10.1097/TXD.0000000000001058, PubMed 33062842
Fasting Status and Circadian Variation Must be Considered When Performing AUC-based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients
Clin Transl Sci, 13 (6), 1327-1335
DOI 10.1111/cts.12833, PubMed 32652886
Tacrolimus Area Under the Concentration Versus Time Curve Monitoring, Using Home-Based Volumetric Absorptive Capillary Microsampling
Ther Drug Monit, 42 (3), 407-414
DOI 10.1097/FTD.0000000000000697, PubMed 31479042
Pharmacodynamic assessment of mycophenolic acid in resting and activated target cell population during the first year after renal transplantation
Br J Clin Pharmacol, 86 (6), 1100-1112
DOI 10.1111/bcp.14218, PubMed 31925806
Measured GFR by Utilizing Population Pharmacokinetic Methods to Determine Iohexol Clearance
Kidney Int Rep, 5 (2), 189-198
DOI 10.1016/j.ekir.2019.11.012, PubMed 32043033
Cardiovascular rEmodelling in living kidNey donorS with reduced glomerular filtration rate: rationale and design of the CENS study
Blood Press, 29 (2), 123-134
DOI 10.1080/08037051.2019.1684817, PubMed 31718316
A novel direct method to determine adherence to atorvastatin therapy in patients with coronary heart disease
Br J Clin Pharmacol, 85 (12), 2878-2885
DOI 10.1111/bcp.14122, PubMed 31495943
Tacrolimus Can Be Reliably Measured With Volumetric Absorptive Capillary Microsampling Throughout the Dose Interval in Renal Transplant Recipients
Ther Drug Monit, 41 (5), 607-614
DOI 10.1097/FTD.0000000000000655, PubMed 31584926
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
Ther Drug Monit, 41 (3), 261-307
DOI 10.1097/FTD.0000000000000640, PubMed 31045868
Statin-associated muscle symptoms in coronary patients: design of a randomized study
Scand Cardiovasc J, 53 (3), 162-168
DOI 10.1080/14017431.2019.1612085, PubMed 31030568
Pharmacogenetics in personalised drug therapy
Tidsskr Nor Laegeforen, 139 (8)
DOI 10.4045/tidsskr.19.0055, PubMed 31062549
A Fully Automated Method for the Determination of Serum Belatacept and Its Application in a Pharmacokinetic Investigation in Renal Transplant Recipients
Ther Drug Monit, 41 (1), 11-18
DOI 10.1097/FTD.0000000000000580, PubMed 30633722
A Method for Direct Monitoring of Atorvastatin Adherence in Cardiovascular Disease Prevention: Quantification of the Total Exposure to Parent Drug and Major Metabolites Using 2-Channel Chromatography and Tandem Mass Spectrometry
Ther Drug Monit, 41 (1), 19-28
DOI 10.1097/FTD.0000000000000578, PubMed 30633723
Longitudinal Study of Tacrolimus in Lymphocytes During the First Year After Kidney Transplantation
Ther Drug Monit, 40 (5), 558-566
DOI 10.1097/FTD.0000000000000539, PubMed 30086087
Effects of marine n-3 fatty acid supplementation in renal transplantation: A randomized controlled trial
Am J Transplant, 19 (3), 790-800
DOI 10.1111/ajt.15080, PubMed 30125457
Estimated glomerular filtration rate in stable older kidney transplant recipients-are present algorithms valid? A national cross-sectional cohort study
Transpl Int, 31 (6), 629-638
DOI 10.1111/tri.13137, PubMed 29453878
Estimating Glomerular Filtration Rate in Kidney Transplant Recipients: Comparing a Novel Equation With Commonly Used Equations in this Population
Transplant Direct, 3 (12), e332
DOI 10.1097/TXD.0000000000000742, PubMed 29536033
Prednisolone and Prednisone Pharmacokinetics in Pediatric Renal Transplant Recipients-A Prospective Study
Ther Drug Monit, 39 (5), 472-482
DOI 10.1097/FTD.0000000000000439, PubMed 28749817
NFAT-regulated cytokine gene expression during tacrolimus therapy early after renal transplantation
Br J Clin Pharmacol, 83 (11), 2494-2502
DOI 10.1111/bcp.13367, PubMed 28686294
Defect related radiative recombination in mono-like crystalline silicon wafers
Phys. Status Solidi A-Appl. Mat., 214 (8), 1700124
DOI 10.1002/pssa.201700124
High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation
Transplantation, 101 (8), e273-e279
DOI 10.1097/TP.0000000000001796, PubMed 28452920
Exposure to Mycophenolate and Fatherhood
Transplantation, 101 (7), e214-e217
DOI 10.1097/TP.0000000000001747, PubMed 28346297
The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation
Br J Clin Pharmacol, 83 (7), 1457-1465
DOI 10.1111/bcp.13248, PubMed 28146606
Low-target tacrolimus in de novo standard risk renal transplant recipients: A single-centre experience
Nephrology (Carlton), 21 (10), 821-7
DOI 10.1111/nep.12738, PubMed 26854648
Prediction of Fat-Free Mass in Kidney Transplant Recipients
Ther Drug Monit, 38 (4), 439-46
DOI 10.1097/FTD.0000000000000305, PubMed 27019101
Treatment with Tacrolimus and Sirolimus Reveals No Additional Adverse Effects on Human Islets In Vitro Compared to Each Drug Alone but They Are Reduced by Adding Glucocorticoids
J Diabetes Res, 2016, 4196460
DOI 10.1155/2016/4196460, PubMed 26885529
Drug target molecules to guide immunosuppression
Clin Biochem, 49 (4-5), 411-8
DOI 10.1016/j.clinbiochem.2015.10.001, PubMed 26453533
Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized Study
Transplantation, 99 (10), 2158-66
DOI 10.1097/TP.0000000000000708, PubMed 25886918
Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning
Ther Drug Monit, 37 (4), 493-500
DOI 10.1097/FTD.0000000000000180, PubMed 25565670
Pharmacist assessment of drug-related problems on an oncology ward
Eur. J. Hosp. Pharm., 22 (4), 194-197
DOI 10.1136/ejhpharm-2014-000510
Intracellular sirolimus concentration is reduced by tacrolimus in human pancreatic islets in vitro
Transpl Int, 28 (10), 1152-61
DOI 10.1111/tri.12617, PubMed 26046470
Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed
Transplantation, 99 (3), 528-32
DOI 10.1097/TP.0000000000000384, PubMed 25148382
Glomerular filtration rate measured by iohexol clearance: A comparison of venous samples and capillary blood spots
Scand J Clin Lab Invest, 75 (8), 710-6
DOI 10.3109/00365513.2015.1091091, PubMed 26426851
[Allogeneic stem-cell transplantation in adults 1985-2012: results and development]
Tidsskr Nor Laegeforen, 134 (16), 1569-75
DOI 10.4045/tidsskr.13.1415, PubMed 25178233
Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling
Br J Clin Pharmacol, 78 (3), 509-23
DOI 10.1111/bcp.12361, PubMed 25279405
The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
Eur J Clin Pharmacol, 70 (6), 685-93
DOI 10.1007/s00228-014-1656-3, PubMed 24658827
Tacrolimus exposure and mycophenolate pharmacokinetics and pharmacodynamics early after liver transplantation
Ther Drug Monit, 36 (1), 46-53
DOI 10.1097/FTD.0b013e31829dcb66, PubMed 24081206
Simultaneous quantification of IMPDH activity and purine bases in lymphocytes using LC-MS/MS: assessment of biomarker responses to mycophenolic acid
Ther Drug Monit, 36 (1), 108-18
DOI 10.1097/FTD.0b013e3182a13900, PubMed 24061448
Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer
Pediatr Blood Cancer, 61 (5), 797-802
DOI 10.1002/pbc.24921, PubMed 24395436
Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation
Transpl Int, 26 (12), 1198-207
DOI 10.1111/tri.12194, PubMed 24118301
Importance of hematocrit for a tacrolimus target concentration strategy
Eur J Clin Pharmacol, 70 (1), 65-77
DOI 10.1007/s00228-013-1584-7, PubMed 24071959
A taste of individualized medicine: physicians' reactions to automated genetic interpretations
J Am Med Inform Assoc, 21 (e1), e143-6
DOI 10.1136/amiajnl-2012-001587, PubMed 24001515
Mycophenolate pharmacokinetics and inosine monophosphate dehydrogenase activity in liver transplant recipients with an emphasis on therapeutic drug monitoring
Scand J Clin Lab Invest, 73 (2), 117-24
DOI 10.3109/00365513.2012.745947, PubMed 23281843
The pharmacokinetics of prednisolone and prednisone in adult liver transplant recipients early after transplantation
Ther Drug Monit, 34 (4), 452-9
DOI 10.1097/FTD.0b013e31825ee3f8, PubMed 22777155
Quantification of 6 glucocorticoids in human plasma by liquid chromatography tandem mass spectrometry: method development, validation, and assessment of matrix effects
Ther Drug Monit, 33 (4), 402-10
DOI 10.1097/FTD.0b013e3182241799, PubMed 21743383
No change in insulin sensitivity in renal transplant recipients converted from standard to once-daily prolonged release tacrolimus
Nephrol Dial Transplant, 26 (11), 3767-72
DOI 10.1093/ndt/gfr153, PubMed 21471328
Determination of cyclosporine, tacrolimus, sirolimus and everolimus by liquid chromatography coupled to electrospray ionization and tandem mass spectrometry: assessment of matrix effects and assay performance
Scand J Clin Lab Invest, 70 (8), 583-91
DOI 10.3109/00365513.2010.531141, PubMed 21039189
Cyclosporine C2 levels have impact on incidence of rejection in de novo lung but not heart transplant recipients: the NOCTURNE study
J Heart Lung Transplant, 28 (9), 919-26
DOI 10.1016/j.healun.2009.05.022, PubMed 19716045
Determination of digoxin and digitoxin in whole blood
J Anal Toxicol, 33 (7), 372-8
DOI 10.1093/jat/33.7.372, PubMed 19796507
Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot study
J Transl Med, 7, 64
DOI 10.1186/1479-5876-7-64, PubMed 19635156
Rimonabant affects cyclosporine a, but not tacrolimus pharmacokinetics in renal transplant recipients
Transplantation, 87 (8), 1221-4
DOI 10.1097/TP.0b013e31819f1001, PubMed 19384170
Pharmacodynamics of mycophenolic acid in CD4+ cells: a single-dose study of IMPDH and purine nucleotide responses in healthy individuals
Ther Drug Monit, 30 (6), 647-55
DOI 10.1097/FTD.0b013e31818955c3, PubMed 18806697
Reduced elimination of cyclosporine A in elderly (>65 years) kidney transplant recipients
Transplantation, 86 (10), 1379-83
DOI 10.1097/TP.0b013e31818aa4b6, PubMed 19034006
Expression of IMPDH1 is regulated in response to mycophenolate concentration
Int Immunopharmacol, 9 (2), 173-80
DOI 10.1016/j.intimp.2008.10.017, PubMed 19010451
Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer
Pediatr Blood Cancer, 50 (3), 710-3
DOI 10.1002/pbc.21133, PubMed 17226852
Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression
Transplantation, 85 (1), 55-61
DOI 10.1097/01.tp.0000296854.68123.03, PubMed 18192912
IMP dehydrogenase basal activity in MOLT-4 human leukaemia cells is altered by mycophenolic acid and 6-thioguanosine
Scand J Clin Lab Invest, 68 (4), 277-85
DOI 10.1080/00365510701724871, PubMed 18609073
Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients
Nephrol Dial Transplant, 23 (3), 1048-53
DOI 10.1093/ndt/gfm632, PubMed 17956893
Real-time PCR determination of IMPDH1 and IMPDH2 expression in blood cells
Clin Chem, 53 (6), 1023-9
DOI 10.1373/clinchem.2006.081968, PubMed 17463174
Determination of inosine monophosphate dehydrogenase activity in human CD4+ cells isolated from whole blood during mycophenolic acid therapy
Ther Drug Monit, 28 (5), 608-13
DOI 10.1097/01.ftd.0000245680.38143.ca, PubMed 17038874
Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome
Am J Transplant, 6 (2), 412-8
DOI 10.1111/j.1600-6143.2005.01184.x, PubMed 16426329
Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment
Scand J Clin Lab Invest, 66 (1), 31-44
DOI 10.1080/00365510500420259, PubMed 16464785
Mycophenolic acid clinical pharmacokinetics influenced by a cyclosporine C2 based immunosuppressive regimen in renal allograft recipients
Transpl Int, 19 (1), 44-53
DOI 10.1111/j.1432-2277.2005.00228.x, PubMed 16359376
C2 monitoring in maintenance renal transplant recipients: is it worthwhile?
Transplantation, 76 (8), 1236-8
DOI 10.1097/01.TP.0000085046.39523.D5, PubMed 14578761
Automated determination of free mycophenolic acid and its glucuronide in plasma from renal allograft recipients
Ther Drug Monit, 25 (3), 407-14
DOI 10.1097/00007691-200306000-00025, PubMed 12766573
Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype
Clin Pharmacol Ther, 72 (3), 333-42
DOI 10.1067/mcp.2002.127396, PubMed 12235455
Effects of DDT on paracetamol half-life in highly exposed mothers in Zimbabwe
Toxicol Lett, 134 (1-3), 147-53
DOI 10.1016/s0378-4274(02)00184-4, PubMed 12191873
Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients
Am J Transplant, 1 (4), 382-6
DOI 10.1034/j.1600-6143.2001.10415.x, PubMed 12099384
Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients
Clin Transplant, 12 (6), 553-6
PubMed 9850449
Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation
Transplantation, 66 (3), 334-9
DOI 10.1097/00007890-199808150-00010, PubMed 9721802
Analysis of methylated 6-mercaptopurine metabolites in human red blood cells: comparison of two methods
Ther Drug Monit, 19 (6), 663-8
DOI 10.1097/00007691-199712000-00010, PubMed 9421108
Optimisation of azathioprine immunosuppression after organ transplantation by pharmacological measurements
BioDrugs, 8 (6), 446-56
DOI 10.2165/00063030-199708060-00005, PubMed 18031107
Patterns of azathioprine metabolites in neutrophils, lymphocytes, reticulocytes, and erythrocytes: relevance to toxicity and monitoring in recipients of renal allografts
Ther Drug Monit, 19 (5), 502-9
DOI 10.1097/00007691-199710000-00003, PubMed 9357091
Possibilities for therapeutic drug monitoring of azathioprine: 6-thioguanine nucleotide concentrations and thiopurine methyltransferase activity in red blood cells
Ther Drug Monit, 19 (3), 318-26
DOI 10.1097/00007691-199706000-00013, PubMed 9200774
Optimization of azathioprine therapy by measuring 6-thioguanine nucleotides and methylated mercaptopurine in renal allograft recipients
Transplant Proc, 27 (6), 3426
PubMed 8540033
Monitoring of azathioprine treatment by determination of 6-thioguanine nucleotide concentrations in erythrocytes
Transplantation, 58 (7), 803-8
PubMed 7940715
Kinetics of mercaptopurine and thioguanine nucleotides in renal transplant recipients during azathioprine treatment
Ther Drug Monit, 16 (1), 13-20
DOI 10.1097/00007691-199402000-00002, PubMed 8160249
Cyclosporine A monitoring in patients with renal, cardiac, and liver transplants: a comparison between fluorescence polarization immunoassay and two different RIA methods
Scand J Clin Lab Invest, 53 (5), 471-7
DOI 10.1080/00365519309092542, PubMed 8210969
DIASTOLIC TIME IN PATIENTS TREATED WITH TIMOLOL OR PLACEBO AFTER ACUTE MYOCARDIAL-INFARCTION
Am. J. Noninvas. Cardiol., 7 (4), 220-224
DOI 10.1159/000470283
Lack of effect of the calcium antagonist isradipine on cyclosporine pharmacokinetics in renal transplant patients
Ther Drug Monit, 13 (6), 490-5
DOI 10.1097/00007691-199111000-00004, PubMed 1837629
[Side effects of antitubercular drugs leading to discontinuation of drug therapy]
Tidsskr Nor Laegeforen, 100 (5), 279-82
PubMed 7385151
Review articles
Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Ther Drug Monit, 43 (2), 150-200
DOI 10.1097/FTD.0000000000000871, PubMed 33711005
Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions
Ther Drug Monit, 42 (3), 360-368
DOI 10.1097/FTD.0000000000000761, PubMed 32304488
Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs
Ther Drug Monit, 38 Suppl 1, S57-69
DOI 10.1097/FTD.0000000000000255, PubMed 26469711
Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation
Ther Drug Monit, 38 Suppl 1, S1-20
DOI 10.1097/FTD.0000000000000287, PubMed 26977997
Therapeutic Drug Monitoring of Belatacept in Kidney Transplantation
Ther Drug Monit, 37 (5), 560-7
DOI 10.1097/FTD.0000000000000179, PubMed 25551406
[Immunosuppressive drugs and the development of skin cancer after organ transplantation]
Tidsskr Nor Laegeforen, 132 (18), 2064-8
DOI 10.4045/tidsskr.12.0389, PubMed 23038197
[Drug interactions and immunosuppression in organ transplant recipients]
Tidsskr Nor Laegeforen, 131 (20), 2000-3
DOI 10.4045/tidsskr.11.0138, PubMed 22016125
[Individualized pharmacotherapy based on cytochrome P-450 (CYP) genotyping]
Tidsskr Nor Laegeforen, 122 (29), 2781-3
PubMed 12523145
[Immunosuppressive agents in organ transplantation]
Tidsskr Nor Laegeforen, 119 (24), 3615-20
PubMed 10563181
[Mycophenolate mofetil--a new immunosuppressive agent]
Tidsskr Nor Laegeforen, 116 (20), 2439-41
PubMed 8928103
Other articles
Therapeutic Drug Monitoring in the Era of Precision Medicine: Achievements, Gaps, and Perspectives-An Interview in Honor of Professor Charles Pippenger
Ther Drug Monit, 43 (6), 719-727
DOI 10.1097/FTD.0000000000000932, PubMed 34654029
Pharmacogenetics in personalised drug therapy
Tidsskr. Nor. Laegeforen., 139 (8), 700-702
The Authors' Reply
Transplantation, 102 (1), e43-e44
DOI 10.1097/TP.0000000000001961, PubMed 28957846
Costimulation Blockade: America First, Canada Second … What About Norway?
Am J Transplant, 17 (8), 2230
DOI 10.1111/ajt.14351, PubMed 28508535
Response to: 'Response to: Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'
Br J Clin Pharmacol, 83 (6), 1357-1358
DOI 10.1111/bcp.13276, PubMed 28374426
Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance
Br J Clin Pharmacol, 83 (6), 1350-1352
DOI 10.1111/bcp.13188, PubMed 28008657
Pharmacology Portal: An Open Database for Clinical Pharmacologic Laboratory Services
Clin Ther, 38 (1), 222-6
DOI 10.1016/j.clinthera.2015.10.015, PubMed 26546404
[Customized drugs?]
Tidsskr Nor Laegeforen, 126 (18), 2364
PubMed 16998544
TDM: report concentration, Css, rather than area under the curve, AUC
Ther Drug Monit, 25 (6), 743
DOI 10.1097/00007691-200312000-00015, PubMed 14639063
[Better therapeutic potential for azathioprine and mercaptopurine]
Lakartidningen, 97 (16), 1999-2000
PubMed 10826362
Books
Materialadministrasjon og kapitalrasjonalisering
In Temahefte, ISI, Oslo, 7, 7 s.
BIBSYS 930568982
Theses
Azathioprine monitoring in renal transplantation
Department of Clinical Pharmacology, Institute of Clinical Biochemistry, Department of Surgery, University of Oslo, Rikshospitalet, [Oslo], 1 b. (flere pag.)
BIBSYS 982283202, ISBN 82-7633-106-8
Bivirkninger av tuberkulostatika
S. Bergan, Oslo, 87 s.
BIBSYS 961713232